Stock Comparison

ABBV vs TARA

AbbVie Inc vs Protara Therapeutics Inc

The Verdict

TARA takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

TARA

Protara Therapeutics Inc

4.5

out of 10

Proceed with Caution

Head-to-Head

$381.1B

Market Cap

$277M

104.8

P/E Ratio

-3.6

5.8%

Profit Margin

N/A

95.6%

Return on Equity

-38.7%

20.2

Debt-to-Equity

N/A

Moderate

Overall Risk

Aggressive

0.1

DVR Score

4.5

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

TARA4.5/10

Protara Therapeutics (TARA) continues to represent a high-risk, high-reward investment opportunity, largely tied to the binary outcome of TARA-002. While the recent FDA Orphan Drug Designation for TARA-002 in specific lymphatic malformations reinforces its potential for market leadership and addresses a significant unmet medical need, recent financial updates temper enthusiasm. Q1 2026 saw a widen...

Full TARA Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.